Novartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenya® (fingolimod) dosing regimen patent
Ad hoc announcement pursuant to Art. 53 LR
Basel, 21 September, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied its petition to rehear the negative decision regarding the validity of US Patent No. 9,187,405, covering a dosing regimen for 0.5mg Gilenya. Novartis plans to file a petition seeking further review of the CAFC’s decision with the US Supreme Court.
In August 2020, the U.S. District Court for the District of Delaware issued a favorable decision and a permanent injunction was granted against HEC Pharma until the expiration of the ’405 patent in December 2027 (including pediatric exclusivity). HEC Pharma was the only remaining Abbreviated New Drug Application (ANDA) filer challenging this patent.
In January 2022, a three-judge panel of the CAFC issued a decision upholding the validity of the dosing regimen patent. HEC subsequently filed a petition for rehearing with the CAFC and, in June 2022, a modified panel from the CAFC issued a reversal of its previous decision and found the patent invalid.
Should generics launch in the US, we expect FY 2022 sales to be negatively impacted by USD 0.3bn. With regard to 2022 Full Year Guidance for Group sales and core operating income growth, we continue to expect both in the mid-single digit range, in constant currencies.
Novartis intends to vigorously defend the validity of the patent and is considering all available options, including current plans to seek review of this decision by petition to the US Supreme Court, a process which may take several months to determine if the petition will be granted.
Previously, Novartis entered into settlement agreements with a number of ANDA filers. Under these settlements, those ANDA filers would have been able to launch a generic version of Gilenya, if approved by FDA, on an agreed upon date that is prior to the expiration of the dosing regimen patent, or earlier than the agreed upon date under certain circumstances. With this decision, HEC and other ANDA filers with FDA approval will potentially be able to launch a generic version of 0.5mg Gilenya imminently, pending any other judicial actions.
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact firstname.lastname@example.org
# # #
Novartis Media Relations
| Richard Jarvis|
Novartis Strategy & Financial
+41 79 576 0723 (mobile)
Novartis US External Communications
+1 862 579 8456
| Meghan O’Donnell|
Novartis Innovative Medicines
+41 61 324 9136 (direct)
+41 79 797 9102 (mobile)
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
|Samir Shah||+41 61 324 7944||Sloan Simpson||+1 862 345 4440|
|Nicole Zinsli-Somm||+41 61 324 3809||Alina Levchuk||+1 862 778 3372|
|Isabella Zinck||+41 61 324 7188||Parag Mahanti||+1 973-876-4912|
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Phoenix Software Delivers a Faster JES3plus® with V1R227.9.2022 13:00:00 CEST | Press release
Phoenix Software releases updates to its product line in September 2022 EL SEGUNDO, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Phoenix Software International, Inc., today announced its intention to make JES3plus V1R2, a derivative work based on IBM’s z/OS® JES3, generally available effective September 30, 2022. This release provides new functionality and integrates continuous delivery items made available over the past twelve months. Thanks to Phoenix’s JES3plus Customer Advisory Council, organizations that migrate to JES3plus can reap the benefits of new features that were ranked in terms of providing true business value to their fellow customers. JES3plus V1R2 Functional Highlights: Parallel SPOOL I/O – Takes full advantage of the Parallel Access Volumes technology supported by modern mainframe DASD through support for up to eight STARTIO channel programs running concurrently for a single SPOOL extent. This is a major improvement over the traditional JES3 approach of allowing only on
Norsk Hydro: Invitation - Hydro's third quarter 2022 results27.9.2022 13:00:00 CEST | Press release
Hydro's third quarter 2022 results will be released at 07:00 CEST (01:00 AM EST, 06:00 GMT), on Tuesday, October 25, 2022. The quarterly report and presentation slides will be available on hydro.com at the same time. Presentation in Oslo Hydro will host an in-person presentation and Q&A, in English, at the Felix Conference Centre at Bryggetorget 3, Oslo, at 08:30 CEST on Tuesday, October 25, 2022. The presentation, by President and CEO Hilde Merete Aasheim and CFO Pål Kildemo, can also be seen on the webcast. To attend the presentation in Oslo, please register your details via this link. There will also be a separate virtual Q&A session at 11:00 CEST. Please register your details using this link to join the conference call. Once registered, you will receive an email containing your dial in number(s) and PINs. Investor contact: Line Haugetraa +4741406376 email@example.com
Norsk Hydro: Presentasjon av Hydros resultat for tredje kvartal 202227.9.2022 13:00:00 CEST | Pressemelding
Hydros resultat for tredje kvartal 2022 blir offentliggjort tirsdag 25. oktober 2022 kl. 07.00 CEST (01:00 AM EST, 06:00 GMT). Kvartalsrapporten og presentasjonsmaterialet blir samtidig gjort tilgjengelig på hydro.com. Presentasjon i Oslo Det blir holdt fysisk presentasjon og Q&A ved Felix Konferansesenter på Bryggetorget 3, Oslo, samme dag, kl. 08.30 CEST. Resultatet blir presentert av konsernsjef Hilde Merete Aasheim og konserndirektør for økonomi og finans Pål Kildemo. Hele presentasjonen kan følges direkte på webcast. For å delta på presentasjonen i Oslo, vennligst registrer dine detaljer via denne lenken. Det vil være også være en separat digital Q&A telefonkonferanse klokken 11:00 CEST. Vennligst benytt denne lenken for å registrere deg til telefonkonferansen. Etter registrering vil du motta en epost med telefonnummer og deltakerkode. Investorkontakt: Line Haugetraa +4741406376 firstname.lastname@example.org
Lytho Appoints Geert Bruinink to Lead Operations in Europe27.9.2022 10:00:00 CEST | Press release
Seasoned Executive Brings a Mix of General Management and Sales Leadership as the Company Expands Reach in Europe for its Creative Workflow and Digital Asset Management (DAM) Software AMSTERDAM, the Netherlands and RALEIGH, N.C., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Lytho, a creative operations platform providing creative workflow and digital asset management (DAM) tools to brand and creative teams, today announced it has hired Geert Bruinink as its Country Manager based in The Netherlands. He will report to Lytho CEO Douglas Thede and have overall responsibility for the company’s European sales and operations. “Geert brings a proven track record of general management and sales leadership skills to Lytho as we extend our presence in Europe,” said Thede. “We’ve seen strong demand for our software because in-house creative teams have grown, and our tools reduce the natural complexity that comes with that growth. We’re thrilled to welcome Geert as a Lythonian and look forward to his contrib
Conagen unveils commercial production of high-purity non-GMO salidroside27.9.2022 10:00:00 CEST | Press release
Ideal for adaptogen supplement solutions and natural preservatives in food and beverages. Bedford, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Conagen announced the commercialization of its 99% high-purity salidroside made by bioconversion technology, an active ingredient from the herbal plant Rhodiola rosea (golden root). Its strong antioxidant properties as an adaptogen are associated with reducing inflammation, protecting against oxidative stress in cells, and providing relief from depression, fatigue, and stress. Salidroside has also been used to alleviate high altitude sickness. Unlike other salidroside products currently on the market, Conagen’s salidroside is non-GMO. Conagen leveraged its industry-leading bioconversion technology to produce clean, sustainable salidroside, identical to the compound naturally found in the Rhodiola rosea plant --- the same technology used to produce non-GMO Rebaudioside M, other steviol glycosides, and bitter blockers for sugar reduction solutions w